



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
Rockville MD 20857

OCT 19 1989

#18

Re: Nimotop  
Docket No. 89E-0104

Charles E. Van Horn, Esq.  
Deputy Solicitor, Solicitor's Office  
U.S. Patent and Trademark Office  
Washington, DC 20231

Dear Mr. Van Horn:

This is in regard to the patent term extension application for U.S. Patent No. 4,406,906 filed by Bayer A.G., under 35 U.S.C. 156. The patent claims the human drug product named Nimotop (nimodipine), New Drug Application number 19-869.

In the April 12, 1989 issue of the Federal Register, the Food and Drug Administration published its determination of the product's regulatory review period, as required under 35 U.S.C. 156(d)(2)(A). The notice provided that on or before October 10, 1988, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. 156 (d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to the notice regarding Nimotop has expired, and FDA has received no such petition. FDA, therefore, considers Nimotop's regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Ronald L. Wilson  
Director  
Health Assessment Policy Staff  
Office of Health Affairs

cc: Louis E. Davidson  
Miles Inc.  
P.O. Box 40  
Elhart, IN 46515